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Defects in germinal center selection
in SLE
Megan Woods, Yong-Rui Zou and Anne Davidson*
Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, New York, NY, USA
Germinal centers (GCs) are the primary site at which clonal expansion and affinity
maturation of B cells occur. B cells encounter antigen and receive T cell help in the GC
light zone (LZ) and then migrate to the dark zone where they proliferate and undergo
somatic mutation before cycling back to the LZ for further rounds of selection. Tolerance
to autoantigens is frequently lost de novo as GC B cells undergo class switching
and somatic mutation. This loss of tolerance is regulated by a variety of mechanisms
including cell death, failure to compete for T cell help, and failure to differentiate into
effector cells. Systemic lupus erythematosus (SLE) is characterized by loss of tolerance
to nucleic acid antigens. While defects in tolerance occur in the naïve repertoire of SLE
patients, pathogenic autoantibodies also arise in the GC by somatic mutation from non-
autoreactive precursors. Several B cell defects contribute to the loss of GC tolerance
in SLE, including polymorphisms of genes encoded by the Sle1 locus, excess TLR7
signaling, defects in FcRIIB expression, or defects of B cell apoptosis. Extrinsic soluble
factors, such as Type-1 IFN and B cell-activating factor, or an increased number of T
follicular helper cells in the GC also alter B cell-negative selection. Finally, defects in
clearance of apoptotic debris within the GC result in BCR-mediated internalization of
nucleic acid containingmaterial and stimulation of autoantibody production by endosomal
TLR-driven mechanisms.
Keywords: SLE, B cell, germinal center, autoimmunity, tolerance mechanisms
Introduction – Germinal Center Formation and Structure
In quiescent lymphoid follicles, a chemokine gradient restricts CCR7+/PSGL-1+ T cells to a central
area and CCR7 /CXCR5+ B cells to a ring surrounding the T cell zone. Major changes in this
structure occur upon antigen encounter. Activated T cells downregulate CCR7 and PSGL-1 and
upregulateCXCR5, promoting theirmigration to the interfollicular zonewhere they contact antigen-
activated B cells that have upregulated CCR7. The interaction of ICOSL on B cells with ICOS on T
cells initiates the differentiation of T follicular helper cells (TFH), whereas T cell help promotes
the expansion of extrafollicular (EF) B cell foci (1–3). B cell fate decision is then regulated by
several factors including the affinity of the B cell receptor (BCR) for antigen, costimulatory signals
from T cells, and the cytokine milieu (4, 5). Some B cells will remain outside the follicle and
upregulate Blimp1, becoming short-lived low-affinity plasmablasts. Other B cells downregulate
EBV-inducedmolecule-2 (EBI2) that interacts with a chemokine-like gradient established by 7α,25-
dihydroxycholesterol (6–9); these cells, as well as CXCR5+ TFH, move inside the follicle to form the
germinal center (GC) (6). Expression of particular transcription and survival factors including Bcl6
and IRF4 in T cells and Bcl6, Myc, andMcl1 in B cells is required for the differentiation and survival
of GC cells [reviewed in Ref. (10, 11)].
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As the GC matures, stromal cells orchestrate the spatial seg-
regation of centrocytes and centroblasts into the light zone (LZ)
and dark zone (DZ) regions, respectively (Figure 1). Follicular
dendritic cells (FDC), usually located inside quiescent B cell fol-
licles (12), form clusters within the developing LZ; these cells
capture and retain immune complexes via the complement recep-
tors, CD21 and CD35 (13, 14). FDCs also produce CXCL13
that recruits CXCR5+ centrocytes and TFH cells into the LZ,
thus forming a platform for cognate B–T cell interactions (15).
By contrast, CXCR4hi centroblasts are segregated in the DZ by
reticular cells expressing high levels of CXCL12 (16). Selection of
B cells begins as early as the pre-GC stage and continues in the
LZ where centrocytes are exposed to FDC-bound native antigen.
High-affinity B cells endocytose and present more antigen to
T cells thereby competing most efficiently for help from TFH.
Centrocytes then upregulate CXCR4 and migrate into the DZ
where they proliferate and accumulate somatic mutations in their
variable regions before downregulating CXCR4 and cycling back
to the LZ for further rounds of affinity-based selection (17–21).
When FDCs are depleted, GC B cells and TFH cells die rapidly,
whereas in the absence of CXCR4, GC B cells are confined to the
LZ and have fewer somatic mutations (20, 22).
Several types of T cells populate the LZ and secrete a variety
of cytokines that drive GC B cell differentiation and effector
functions. The characteristics of TFH cells have recently been
reviewed and will not be further addressed here (23–25). GC
regulatory T cells have also been described (26). Foxp3+CD4+ T
follicular regulatory cells (TFR) express CXCR5 and Bcl6 and act
by downregulating CD80 and CD86 expression on B cells, thereby
diminishing the strength of cognate B–T interactions (27, 28).
Qa1-restricted ICOSL+CXCR5+ regulatory CD8 T cells interact
directly with Qa1-expressing TFH cells (29). The balance between
TFH andTFR sets the threshold at which B cells compete for T cell
help; this in turn regulates B cell entry and dwell time in the DZ.
Regulation of B Cell Selection in
Germinal Centers
Most high-affinity naïve autoreactive B cells are anergized or
deleted before the GC stage (30, 31). However, mechanisms need
to be in place to purge those B cells that increase their autoreactiv-
ity or acquire autoreactivity de novo as a result of random somatic
mutations occurring in the GC (31). How this is achieved is still
not fully understood. Elegant studies have been performed in
the hen egg lysozyme (HEL)/anti-HEL model using HEL variants
with differing affinities and patterns of tissue expression. These
studies have led to the paradigm that engagement of the BCR
by self-antigen but in the absence of T cell costimulatory signals
results in B cell death before the plasma cell stage. Tolerance can be
broken if the self-antigen crossreacts with a foreign antigen, and
B cells are therefore able to recruit help from anti-foreign T cells,
or if the self-antigen is not present in high enough concentrations
within the GC to mediate deletion (32).
Regulation of autoreactivity involving nucleic acid autoanti-
gens is, however, more complex because low-affinity IgM anti-
nuclear autoantibodies are required to opsonize and promote
clearance of nucleic acid antigens that are shed from apoptotic
cells; loss of this IgM can induce or accelerate autoimmunity
(33). By contrast, IgG autoantibodies directed to nuclear autoanti-
gens can penetrate tissues and initiate inflammatory cascades.
There has been much work directed at understanding whether
the class-switched autoreactive B cells that arise in systemic lupus
erythematosus (SLE) are derived from naïve autoreactive B1,
marginal zone, or follicular B cells that undergo clonal expan-
sion either inside or outside the GC or whether they arise de
novo by somatic mutation. Mice with site-directed transgenes
that encode autoreactive immunoglobulin genes capable of class
switching and somatic mutation have been used to address this
question.
i. D42 is an anti-dsDNA hybridoma derived from the NZB/W
lupus-prone strain. Anti-DNA activity of D42 is conferred by
its basicVHCDR3 region aswell as by its associated light chain
Vκ16–104. In non-autoimmune D42 heavy chain transgenic
(D42hTg) mice, autoreactivity is regulated by clonal deletion
at the immature stage, clonal anergy, and receptor editing.
D42 hybridomas derived from these mice have low-affinity
for DNA and use diverse light chains. In lupus-prone D42hTg
NZB/Wmice, clonal deletion initially appears intact but high-
affinity IgG anti-DNA antibodies appear in the serum with
FIGURE 1 | Schematic of the germinal center: germinal centers
consist of two major anatomic regions. The major cell types in the
light zone (LZ) and dark zone (DZ) are shown. B cell centrocytes undergo
selection in the light zone and then migrate to the dark zone where the B
cell centroblasts proliferate and undergo somatic mutation before cycling
back to the light zone. After several cycles, B cells differentiate into
memory cells or plasma cells and exit the germinal center. Defects in
germinal center cells or functions that result in spontaneous germinal
center formation and loss of tolerance to nucleic acid antigens are shown
on the right.
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age. In this strain, receptor editing of the light chain results
in a preference in the naïve repertoire for Vκ4-55*01 that
confers low-affinity polyreactivity. Nevertheless, nearly all
IgG anti-DNA hybridomas from D42hTg NZB/W mice use
Vκ16–104 rearranged to Jk5, a combination generated by
receptor editing that confers high affinity for DNA. Thus,
receptor editing can protect from autoimmunity but may also
generate potentially dangerous antibodies (34–37). Using cell
sorting and single cell analyses, we have shown that B cells
expressing a restricted repertoire of light chains, including
Vκk4–55*01, that confer no or low-affinity autoreactivity
are positively selected into the naïve B cell pool of D42hTg
NZB/W mice. By contrast, D42/Vκ16-104 expressing B cells
are mostly deleted by the late transitional B cell stage, but are
then preferentially selected and expanded in the GC as the
mice age (38).
ii. The 3H9 heavy chain, also derived from an anti-DNA
hybridoma, pairs with a wide variety of light chains to gener-
ate DNA and non-DNA binding, as well as low-affinity anti-
cardiolipin antibodies (39). In non-autoimmune 3H9 heavy
chain transgenic (3H9hTg) mice, autoreactivity is regulated
by receptor editing and anergy (40). Those 3H9 B cells that do
enter the GC and undergo somatic mutations fail to develop
into plasma cells (41). By contrast, 3H9-encoded anti-dsDNA
antibodies using pathogenic light chains arise in autoimmune
strains (42). We showed in 3H9hTg NZB/W and NZW/BXSB
mice that the GC and plasma cell repertoire is dominated by
3H9/Vκ5 pairs and that the Jκ region influences the avid-
ity of such pairs for chromatin and the stringency for GC
entry. The acquisition of somaticmutations then increases the
affinity for chromatin and confers new binding for DNA or
cardiolipin (43).
Taken together, the studies in D42 and 3H9 transgenic NZB/W
mice show that failure to regulate GC entry and clonal expansion
of rare naïve high-affinity autoreactive B cells (D42) and failure
to regulate autoimmunity acquired by somatic mutation in the
GC (3H9) can both contribute to loss of tolerance to nuclear
autoantigens.
One approach to address the same question in humans is to
express immunoglobulin genes from single B cells and test them
for autoreactivity. Pioneering studies showed a high frequency
of autoreactivity among early immature bone marrow B cells
that is subsequently censored during the late immature and early
transitional stages. These tolerance checkpoints are compromised
in patients with SLE even during periods of remission (44, 45).
Normal individuals also regulate autoreactivity within the IgM
memory and bone marrow plasma cell compartments (46, 47).
Sanz and colleagues showed that autoreactive VH4-34 encoded
9G4 idiotype+ B cells from normal tonsils have an anergic phe-
notype and fail to mature to a GC phenotype or enter the memory
compartment. 9G4 B cells from SLE patients are overrepresented
among GC and memory cells, suggesting tolerance failure in the
GC (48). By contrast, single cell analyses have demonstrated that
autoreactive B cells from the class-switched memory compart-
ment can be derived fromnon-autoreactive precursors (49). Thus,
in humans, as in mice, failure of regulation of autoreactive B cells
can occur both at theGC entry checkpoint and at the post-somatic
mutation checkpoint.
Many Models of SLE are Characterized By
Spontaneous GC Development
The Sle1 mouse that bears a region of chromosome 1 derived
from the lupus-proneNZM2410 strain develops spontaneousGCs
and high titers of anti-chromatin autoantibodies without systemic
inflammation or clinical lupus (50, 51). The Sle1b locus harbors
polymorphisms in genes from the signaling lymphocyte activation
molecule (SLAM) family of receptors that contribute to loss of
GC tolerance in a B cell-intrinsic manner. Paradoxically, Sle1b B
cells manifest lower Ca2+ flux and less cell death than their wild-
type counterparts, protecting them from negative selection in the
GC (52). They also form poorer T–B conjugates, perhaps allowing
them to interact more promiscuously with T cells (53).
Germinal center B cells upregulate the inhibitory FcRIIB recep-
tor and this regulates the final differentiation of memory B and
plasma cells. Failure to upregulate FcRIIB on GC B cells occurs in
the Sle1 model (54) and in human lupus patients (55) resulting in
loss of tolerance at the late B cell checkpoint. In addition, several
lupus models have a polymorphism that confers lower levels of
expression of FcRIIB (56); lupus in these strains is attenuated by
restoration of FcRIIB on B cells (57).
Not surprisingly, TFH numbers influence GC reaction and reg-
ulate tolerance to autoantigens. One interesting model is deficient
in Roquin1, an RNA-binding protein that post-transcriptionally
represses expression of ICOS and the costimulatory molecule
Ox-40 (58). Roquin1-deficient mice have increased numbers of
TFH and develop GC-dependent autoimmunity with a lupus-like
phenotype (59). In humans, increased expression of Ox-40L on
myeloid antigen-presenting cells is induced by RNA-containing
immune complexes and this in turn amplifies TFH responses once
tolerance is broken (60). Failure of TFR can also induce lupus.
For example, mice deficient in GC CD8 Tregs have large GCs,
autoantibodies, and lupus-like glomerulonephritis (29).
Innate immune pathways also contribute to spontaneous GC
formation in lupus mice. We showed that administration of a
single dose of IFN-expressing adenovirus to young NZB/W and
NZW/BXSB mice induces GC formation and autoantibodies in
a T cell-dependent manner (61). Using single cell analysis and
expression of 3H9 heavy/light chain pairs of interest, we further
showed in NZW/BXSB mice that type-I IFN relaxes the strin-
gency for GC entry and clonal expansion resulting in increased
autoreactivity of the GC-derived repertoire (43).
Type-1 IFNs are induced through the activation of endo-
somal TLRs that specifically recognize nucleic acids. TLR7 is
needed to generate antibodies against RNA antigens and car-
diolipin, whereas TLR9 is needed for spontaneous genera-
tion of anti-dsDNA autoantibodies. TLR7-overexpressing mice
develop severe inflammatory kidney disease and increased mor-
tality (62), whereas disease is ameliorated in TLR7-deficient
lupus mice (63). Surprisingly, TLR9-deficient lupus mice have
increased autoimmune disease; this is associated with greater
production of anti-RNA autoantibodies (63, 64). Lupus-prone
mice deficient in both TLR7 and TLR9 or in their adaptor
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protein MyD88 do not develop either autoantibodies or lupus
nephritis (63, 65).
Mice deficient in TLR7 on B cells have a significantly reduced
GC response upon challenge with an RNA virus and have a
relative decrease in the size of the DZ where proliferation and
somatic mutation occur. This results in decreased production of
high-affinity anti-viral antibodies (66). In lupus models, B cell-
intrinsic TLR7 expression drives GC formation and autoantibody
production (67). In the BWAS /  model in which B cells are
deficient in theWiskott–Aldrich syndrome protein, GC formation
depends on B cell-intrinsic TLR7 (64) but is unaffected by Type 1
IFN (American College of Rheumatology, Abstract 2870, 2014).
In the pristane model of SLE, induction of TLR7 is downstream of
Type-I IFN (68). These studies both suggest that the mechanism
of action of TLR7 in GC formation and autoantibody induction is
notmediated via induction of Type-I IFN.Using 3H9NZW/BXSB
male mice that bear two copies of TLR7, we showed that excess
TLR7, like excess Type-I IFN, results in the failure of exclusion
of high-affinity autoreactive B cells from the GC, with subsequent
clonal expansion and somatic mutation of these cells that then can
enter the plasma cell compartment (69).
The Role of Baff in the Germinal Center
B cell-activating factor (BAFF) is made by stromal cells in the
secondary lymphoid organs including FDCs. The interaction of
BAFF with BAFF-R is required for B cell survival and regulates
the selection of naïve autoreactive B cells whereas BAFF excess
can induce lupus-like autoimmunity (70). The GC is in general
a BAFF poor environment, and expression of BAFF receptors
is also downregulated, with BAFF-R being the sole receptor on
GC B cells (71). BAFF and BAFF-R KO mice form smaller GCs
that decline prematurely, indicating that BAFF is needed for GC
maintenance (72). The mechanism for this dependence is not
yet clear. BAFF influences ICOSL expression on B cells, thus
regulating the ability of B cells to promote TFH expansion during
GC development (73). TFH, in turn, produce BAFF and this may
enhance the survival and selection of high-affinity B cells (74).
Acting via a receptor other than BAFF-R, BAFF is required for
the development of a mature FDC reticulum (72). Furthermore,
activated T cells are also responsive to BAFF, releasing IFNγ that
amplifies autoimmune effector responses (75). TFH cells express
both BAFF-R and BCMA. In a lupus-prone strain with T cell-
specific BCMA deficiency, TFH cells are expanded and signaling
through BAFF-R results in enhanced IFNγ release (76). Whether
BAFF modulates the selection of autoreactive B cells in the GC
either in mice or humans is not yet known.
Extrafollicular Clonal Expansion and
Somatic Mutation in SLE
Extrafollicular B cells can undergo clonal expansion and limited
somatic mutation. Although T cell help is usually rather limited
in EF foci, TFH-like cells have been found in these foci in several
lupus-prone mouse strains, raising the possibility that somatic
mutations leading to high-affinity autoreactivity can occur in
these sites without the usual regulatory mechanisms in place
(77, 78). In NZW/BXSB mice, GCs are found early in the disease
but then disappear around the time of disease onset and are
replaced by a disorganized splenic architecture with many EF
TFH cells (79). Induction of class-switched autoreactivity outside
GCs also occurs in BAFF transgenic mice; this requires MyD88
but not T cell help suggesting that under some circumstances,
autoreactivity can be driven solely by innate mechanisms (80).
Whether humans with lupus generate autoantibodies through this
mechanism has not yet been determined. Recent studies in the
9G4 system have shown that during SLE flares, activated naïve B
cells are the source of oligoclonal expansions of plasma cells with
only low frequencies of somatic mutation, suggesting that some
autoantibodies may derive from EF sources in humans (81).
Cell Death in Germinal Centers
Germinal center B cell survival is a result of the balance of pro-
survival and pro-apoptotic molecules whose expression is regu-
lated by affinity-based BCR signals, extrinsic signals from other
cells, including cytokines and contact-dependent signals, and
stochastic effects, that are either random or reflect local signals at
critical times (11). The deathmolecule Fas is highly upregulated in
GC B cells and its loss increases the size of the GC but decreases
affinity maturation as low-affinity antigen-specific B cells fail to
die (82). Similarly, transgenic overexpression of the anti-apoptotic
Bcl2 protein results in survival of low-affinity antigen-specific B
cells and B cells cross-reactive to self-antigens (83). More recent
studies have dissected the role of individual Bcl2 family members
in GC and post-GC B cell survival and selection (84).
Given the high death rate in the GC, specialized mechanisms
are in place to clear dead cells before necrotic material acti-
vates innate pathways that could induce autoimmunity. Apop-
totic cells are opsonized by soluble molecules, such as IgM, C1q,
and MFGE8, and/or are rapidly cleared by highly phagocytic
tingible body macrophages that express a large variety of scav-
enger receptors (85). C1q deficiency is a highly penetrant genetic
cause of SLE in humans (86). MFGE8 recognizes phosphatidyl
serine on apoptotic cells in the GC. Its absence in mice results
in the induction of autoantibodies with age; this loss of toler-
ance is accelerated by repeated immunizations that induce GC
formation (87).
Targeting the GC in SLE
Considering the important role of the GC in the acquisition of
autoreactivity in SLE, targeting of the GC has been a major focus
of therapeutic endeavor. Early studies using the costimulatory
antagonists, anti-CD40L, to abort ongoing GCs or CTLA4Ig to
prevent GC formation were highly effective at preventing lupus
onset in mouse models in which GCs predominate as a source of
autoantibodies. A short-term combination of CTLA4Ig and anti-
CD40L was even more effective than either agent alone (88). We
showed that in NZB/W mice, this was due to tolerance induction
in the GCs, preventing the formation of cross-reactive autoan-
tibodies upon immunization with foreign antigen (89). Similar
restoration of tolerance occurs after administration of an agonist
antibody to CD137 (4-1BB) (90). Other GC targets include TLR7
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and TLR pathways, BAFF, ICOS that is important not only for GC
development but also for the function of effector T cells, and IL-
21 that is expressed both by GC and EF TFH cells. An alternate
strategy is to increase clearance of nucleic acids using RNAse or
DNAse.
In mouse models, therapies targeting the GC lose efficacy once
long-lived autoreactive memory and plasma cells have already
developed (88). Class-switched memory cells do not need to
reenter the GC to rapidly differentiate into plasma cells, and
long-lived plasma cells require neither antigen nor T cells to
survive. GC-directed therapy might therefore be most effective
in the early stages of disease or as maintenance therapy during
disease quiescence. Another potential use of GC-directed therapy
might be to prevent the emergence of autoantibodies that arise
in ectopic tissue GCs during inflammation and are directed to
tissue antigens, such as vimentin (91). Finally, it is possible that
targeting ectopic TFH could prevent ongoing formation of EF foci
of short-lived plasma cells.
Conclusion
Defective tolerance induction in the GC is a feature of many
SLE models and can be due both to impaired selection of naïve
autoreactive B cells into the GC and impaired regulation of B cells
that acquire autoreactivity by somatic mutation. Defects in GC
T cells and insufficient clearance of the large numbers of dead
cells that are generated in the GC can lead to loss of tolerance to
nuclear autoantigens. Impaired signaling through theBCR leading
to insufficient B cell death and excess innate signals leading to a
decrease in stringency of B cell selection both lead to increased
B cell autoreactivity. Many strategies are currently being tested
for targeting of the GC, but the clinical efficacy and optimal
applications of this approach remain to be tested in humans.
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